Sareum Regulatory News (SAR)

SAREUM HOLDINGS PLC

("Sareum")

Share price movement

Sareum, the specialist cancer drug discovery and development business, notes the recent movement in its share price and the Board would like to advise the market that, having published its interim results for the period ended 31 December 2015 on 24 February 2016, it is not aware of any undisclosed reason for this rise.

Sareum Holdings plc

Tim Mitchell 01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting 020 7220 1666

Hybridan LLP (Co-Broker)

Claire Noyce / William Lynne 020 3764 2341/2342

The Communications Portfolio (Media

 enquiries)

Ariane Comstive

 Ariane.comstive@communications-portfolio.co.uk 07785 922 354

 Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL(R) can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

Checkpoint Kinase 1 (CHK1) is important in controlling the way many cancer cells respond to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy. Inhibition of CHK1 affects the ability of the cell to repair this damage and can therefore potentiate the effect of certain chemotherapeutic drugs. The clinical candidate CHK1 inhibitor, known as CCT245737, could potentially treat a range of cancers including pancreatic, bowel and non-small cell lung cancer (NSCLC) in combination with DNA-damaging chemotherapy drugs and/or radiotherapy. The inhibitor could also potentially treat certain neuroblastoma, lymphoma and acute myeloid leukaemia (AML) types when dosed alone.